Citadel Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Citadel Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.8K	Buy	35,300 +22,800	+182%	+$38.4K	﹤0.01%	12364
2025 Q4	$20.9K	Sell	12,500 -105,500	-89%	-$183K	﹤0.01%	12336
2025 Q3	$199K	Sell	118,000 -117,400	-50%	-$139K	﹤0.01%	11268
2025 Q2	$214K	Buy	235,400 +227,400	+2,843%	+$135K	﹤0.01%	10533
2025 Q1	$3.61K	Buy	8,000 +3,000	+60%	+$1.76K	﹤0.01%	13950
2024 Q4	$2.51K	Sell	5,000 -58,800	-92%	-$43.2K	﹤0.01%	14075
2024 Q3	$57.8K	Buy	63,800 +32,500	+104%	+$30.1K	﹤0.01%	11750
2024 Q2	$31.2K	Buy	31,300 +9,900	+46%	+$10.9K	﹤0.01%	12228
2024 Q1	$31.7K	Buy	21,400 +18,100	+548%	+$20.5K	﹤0.01%	12649
2023 Q4	$3.6K	Sell	3,300 -12,500	-79%	-$13.7K	﹤0.01%	13576
2023 Q3	$18.6K	Buy	15,800 +10,700	+210%	+$14.6K	﹤0.01%	12684
2023 Q2	$7.19K	Sell	5,100 -18,200	-78%	-$25.2K	﹤0.01%	13384
2023 Q1	$35K	Buy	23,300 +6,800	+41%	+$9.49K	﹤0.01%	12588
2022 Q4	$19.3K	Buy	+16,500	New	+$20.8K	﹤0.01%	13176
2022 Q2	–	Sell	-27,600	Closed	-$43K	–	13554
2022 Q1	$43K	Sell	27,600 -22,300	-45%	-$34.6K	﹤0.01%	12895
2021 Q4	$122K	Sell	49,900 -33,500	-40%	-$78.4K	﹤0.01%	12498
2021 Q3	$210K	Buy	83,400 +56,900	+215%	+$146K	﹤0.01%	11890
2021 Q2	$76K	Buy	26,500 +14,800	+126%	+$38.3K	﹤0.01%	13109
2021 Q1	$28K	Sell	11,700 -17,000	-59%	-$40.8K	﹤0.01%	13041
2020 Q4	$51K	Buy	+28,700	New	+$40.1K	﹤0.01%	10560
2020 Q3	–	Sell	-12,500	Closed	-$11K	–	10444
2020 Q2	$11K	Sell	12,500 -5,000	-29%	-$4.4K	﹤0.01%	9624
2020 Q1	$14K	Buy	+17,500	New	+$17.4K	﹤0.01%	9368
2019 Q2	–	Sell	-22,100	Closed	-$29K	–	9547
2019 Q1	$29K	Buy	+22,100	New	+$27.5K	﹤0.01%	9002
2018 Q4	–	Sell	-31,204	Closed	-$64K	–	9483
2018 Q3	$64K	Buy	+31,204	New	+$65.5K	﹤0.01%	8743
2018 Q2	–	Sell	-12,916	Closed	-$30K	–	9087
2018 Q1	$30K	Buy	+12,916	New	+$30.3K	﹤0.01%	8051
2017 Q4	–	Sell	-14,059	Closed	-$35K	–	8233
2017 Q3	$35K	Sell	14,059 -2,400	-15%	-$5.95K	﹤0.01%	7258
2017 Q2	$45K	Buy	+16,459	New	+$46K	﹤0.01%	7121
2017 Q1	–	Sell	-18,974	Closed	-$60K	–	7778
2016 Q4	$60K	Buy	+18,974	New	+$58.3K	﹤0.01%	6816
2016 Q1	–	Sell	-64,057	Closed	-$212K	–	7413
2015 Q4	$212K	Buy	64,057 +53,278	+494%	+$159K	﹤0.01%	5732
2015 Q3	$26K	Buy	10,779 +4,088	+61%	+$10.6K	﹤0.01%	8011
2015 Q2	$20K	Sell	6,691 -2,602	-28%	-$10.1K	﹤0.01%	8152
2015 Q1	$37K	Buy	9,293 +2,850	+44%	+$9.86K	﹤0.01%	7574
2014 Q4	$19K	Buy	6,443 +5,700	+767%	+$15.4K	﹤0.01%	7846
2014 Q3	$2K	Buy	+743	New	+$1.79K	﹤0.01%	8000
2014 Q2	–	Sell	-1,859	Closed	-$5K	–	8136
2014 Q1	$5K	Buy	+1,859	New	+$5.47K	﹤0.01%	7645
2013 Q4	–	Sell	-11,275	Closed	-$35K	–	7084
2013 Q3	$35K	Sell	11,275 -11,027	-49%	-$34.9K	﹤0.01%	5959
2013 Q2	$71K	Buy	+22,302	New	+$71.4K	﹤0.01%	5458

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's LCTX Position: Q1 2026 in Review

Citadel Advisors reduced its Lineage Cell Therapeutics (LCTX) stake by 74% in Q1 2026, selling an estimated $634K and leaving 130,948 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #11348.

Citadel Advisors first reported a position in LCTX in Q2 2013 and has held it in 45 quarters since. The position peaked at $847K in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

Citadel Advisors held 130,948 shares of Lineage Cell Therapeutics worth $207K as of Q1 2026.
Citadel Advisors sold 376,104 Lineage Cell Therapeutics shares in Q1 2026, an estimated $634K.
Lineage Cell Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11348 holding.
Citadel Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 45 quarters since.
Citadel Advisors's Lineage Cell Therapeutics position peaked at $847K in Q4 2025.
130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.